Evidence map›Paper›PMID 18506707›Full record

ArticleAmerican journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics2009

Methionine sulfoxide reductase: a novel schizophrenia candidate gene.

Consuelo Walss-Bass, Maria Clara Soto-Bernardini, Teresa Johnson-Pais, Robin J Leach, Alfonso Ontiveros, Humberto Nicolini, Ricardo Mendoza, Alvaro Jerez, Albana Dassori, Ivan Chavarria-Siles and 2 more

Abstract read
In one paragraph

Article in American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 49 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Convergent genomic and pharmacological evidence of PI3K/GSK3 signaling alterations in neurons from schizophrenia patients.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2021
    Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. HDAC1 links early life stress to schizophrenia-like phenotypes.Proceedings of the National Academy of Sciences of the United States of America · 2017
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 4 countries.

Consuelo Walss-BassDepartment of Psychiatry, The University of Texas Health Science Center at San Antonio, USA. walss@uthscsa.edu
Maria Clara Soto-Bernardini
Teresa Johnson-Pais
Robin J Leach
Alfonso Ontiveros
Humberto Nicolini
Ricardo Mendoza
Alvaro Jerez
Albana Dassori
Ivan Chavarria-Siles
Michael A Escamilla
Henriette Raventos
The University of Texas Health Science Center at San Antonio · USUniversidad de Costa Rica · CRUnidad de Cirugía Cardiovascular de Guatemala · GTUniversidad Autónoma de Nuevo León · MXUniversidad Nacional Autónoma de México · MXUniversity of California, Los Angeles · US

Funding

POPULATION BASED MAPPING OF SCHIZOPHRENIA GENESR01MH061884 · NIMH · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI ESCAMILLA, MICHAEL A · 2000 to 2011
$6.0M
GENETICS OF SCHIZOPHRENIA IN LATINO POPULATIONSR01MH060881 · NIMH · UNIVERSITY OF TEXAS HLTH SCI CTR SAN ANT · PI ESCAMILLA, MICHAEL A · 2000 to 2003
$2.1M
NIMH NIH HHS MH-60881NIMH NIH HHS R01 MH060881NIMH NIH HHS R01 MH061884NIMH NIH HHS R01-MH61884
6 · The paper itself

Abstract

Methionine sulfoxide reductase (MSRA) is an antioxidant enzyme implicated in protection against oxidative stress and protein maintenance. We have previously reported the association of marker D8S542, located within the MSRA gene, with schizophrenia in the Central Valley of Costa Rica (CVCR). By performing fine mapping analysis, we have now identified a potential three-marker at risk haplotype within MSRA in the same CVCR sample, with a global P-value slightly above nominal significance (P = 0.0526). By sequencing the MSRA gene in individuals carrying this haplotype, we identified a novel 4-base pair deletion 1,792 bases upstream of the MSRA transcription start site. This deletion was significantly under-transmitted to schizophrenia patients in the CVCR sample (P = 0.0292) using FBAT, and this was replicated in a large independent sample of 321 schizophrenia families from the Hispanic population (P = 0.0367). These findings suggest a protective effect of the deletion against schizophrenia. Further, MSRA mRNA levels were significantly lower in lymphoblastoid cell lines of individuals homozygous for the deletion compared to carriers of the normal allele (P = 0.0135), although significance was only evident when genotypes were collapsed. This suggests that the deleted sequence may play a role in regulating MSRA expression. In conclusion, this work points towards MSRA as a novel schizophrenia candidate gene. Further studies into the mechanisms by which MSRA is involved in schizophrenia pathophysiology may shed light into the biological underpinnings of this disorder.

Indexed as

Genetic Predisposition to DiseaseLinkage DisequilibriumAllelesExonsFemaleGene FrequencyGenotypeHaplotypesHumansMaleMethionine Sulfoxide ReductasesOxidoreductasesSchizophreniamethionine sulfoxide reductaseMethionine Sulfoxide ReductasesOxidoreductases

Identifiers

PMID18506707
PMCPMC3781017
OpenAlexW1982086713

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.